Moreover, the identification of atherogenic targets, such as CD36 in macrophages (41), might lead to the identification of druggable targets and hence to the development of new therapeutic strategies to treat atherosclerotic disease patients that are at a very high risk to suffer a transient ischemic attack, stroke or acute coronary syndrome. Here, CD36 is linked to transient ischemic attack.